These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12940538)

  • 1. Mechanisms and consequences of sympathetic hyperactivity in renal disease.
    Amann K; Veelken R
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S81-92. PubMed ID: 12940538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between chronic kidney disease prevalence and end-stage renal disease risk.
    Hallan SI; Vikse BE
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):286-91. PubMed ID: 18408480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kidney and the neurogenic control of blood pressure in renal disease.
    Campese VM
    J Nephrol; 2000; 13(3):221-4. PubMed ID: 10928299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypertension and renal disease].
    Kamper AL; Pedersen EB; Strandgaard S
    Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The kidneys and hypertension].
    Hausberg M; Mann J; Kühn K
    Dtsch Med Wochenschr; 2008 Sep; 133(37):1853-6. PubMed ID: 18770487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Which optimal antihypertensive bitherapy for kidney patients?].
    Bonne JF; Shahapuni I; Mailliez S; Oprisiu R; Temmar M; Choukroun G; Massy ZA; Fournier A
    Nephrol Ther; 2007 Jun; 3(3):79-88. PubMed ID: 17540309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertension and 24-hours blood pressure monitoring in kidney diseases].
    Csiky B; Wittmann I; Nagy J
    Orv Hetil; 2004 Feb; 145(7):323-6. PubMed ID: 15049046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympathetic activation in cardiovascular and renal disease.
    Grassi G; Arenare F; Pieruzzi F; Brambilla G; Mancia G
    J Nephrol; 2009; 22(2):190-5. PubMed ID: 19384835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension and the kidney.
    Wiederkehr M; Toto R; Fenves AZ; Ram CV
    Semin Nephrol; 2005 Jul; 25(4):236-45. PubMed ID: 16202696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting renal function in the hypertensive patient: clinical guidelines.
    Bakris GL
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):112S-119S. PubMed ID: 15837554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients.
    Vonend O; Rump LC; Ritz E
    Semin Dial; 2008; 21(4):326-30. PubMed ID: 18627567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic renal disease. Primary care identification].
    Hanset M
    Rev Med Brux; 2007; 28(5):465-8. PubMed ID: 18069523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes and consequences of increased arterial stiffness in chronic kidney disease patients.
    Gusbeth-Tatomir P; Covic A
    Kidney Blood Press Res; 2007; 30(2):97-107. PubMed ID: 17374960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.